0000000000225689

AUTHOR

Etienne Martin

showing 12 related works from this author

Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how?

2014

Even in the current era of dose-escalated radiotherapy for prostate cancer, biochemical recurrence is not uncommon. Furthermore, biochemical failure is not specific to the site of recurrence. One of the major challenges in the management of prostate cancer patients with biochemical failure after radiotherapy is the early discrimination between those with locoregional recurrence only and those with metastatic disease. While the latter are generally considered incurable, patients with locoregional disease may benefit from emerging treatment options. Ultimately, the objective of salvage therapy is to control disease while ensuring minimal collateral damage, thereby optimizing both cancer and t…

MaleQuality ControlOncologyBiochemical recurrencemedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentBrachytherapyBrachytherapySalvage therapyBone Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineAdenocarcinomaRadiosurgeryMultimodal Imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineManagement of prostate cancerProstate cancerInternal medicinemedicineHumansMulticenter Studies as TopicRadiology Nuclear Medicine and imagingComputingMilieux_MISCELLANEOUSProstatectomySalvage TherapyLymphatic Irradiationbusiness.industryPalliative CareProstatic NeoplasmsCancerAndrogen AntagonistsRadiotherapy DosageProstate-Specific Antigenmedicine.diseaseCombined Modality Therapy3. Good healthRadiation therapyProstate-specific antigenOncologyLymphatic MetastasisDose Fractionation RadiationRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessRadiotherapy Image-Guided
researchProduct

Prostate Metabolism After the Completion of Exclusive Radiation Is More Depleted After Seeds Brachytherapy Compared to External Beam Radiation Therap…

2012

International audience; Biochemical outcome after radiation therapy requires a protracted time. PSA decreases slowly over time so that it is difficult to differentiate immediately after the completion of radiation the impact of radiation in the prostate using brachytherapy or external radiotherapy. At 3 months, the mean PSA values were similar between the 2 groups: 2.54 ng/mL (±1.59) in the EBRT group and 1.88 ng/mL (±1.14) in the PPI group (p=0.23). For Choline levels, 3-months Choline / Baseline Choline ratios were 1.13 (±0.60) after EBRT vs. 0.45 (±0.23) in the PPI group (p=0.003). Similar results were observed for Citrate levels: 3-months Citrate level / Baseline Citrate level ratios we…

Cancer ResearchRadiation[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingbusiness.industrymedicine.medical_treatmentBrachytherapyExternal beam radiation[INFO.INFO-IM] Computer Science [cs]/Medical ImagingMetabolismmedicine.disease3. Good healthRadiation therapychemistry.chemical_compoundProstate cancermedicine.anatomical_structureOncologychemistryProstatemedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingCholineRadiology Nuclear Medicine and imagingExternal beam radiotherapyNuclear medicinebusiness
researchProduct

Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma.

2017

International audience; Purpose. - Spermatic cord sarcoma is a rare disease, which management remains controversial due to the lack of guidelines. The standard therapeutic approach is surgical: wide soft-tissue resection with radical inguinal orchidectomy, The diagnosis is made during the analysis of the specimen. The high rate of local recurrence indicates adjuvant radiotherapy of the tumor bed. The aim of this series is to determine the efficacy and safety of postoperative intensity-modulated radiotherapy for spermatic cord sarcomas. Patients and methods. - Our series included five consecutive cases of spermatic cord sarcoma treated between 2011 and 2014. The indications for radiotherapy …

LeiomyosarcomaMaleOrgans at Risk[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatment030232 urology & nephrologyParatesticular tumor[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine0302 clinical medicineMedicineOrchiectomy[ SDV.IB ] Life Sciences [q-bio]/BioengineeringPatternsFederationRapidarc[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingCancerAged 80 and overSpermatic CordSarcomaRadiotherapy DosageLiposarcomaMiddle AgedRetroperitoneal Sarcoma3. Good healthmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisGenital Neoplasms MaleSoft-Tissue Sarcoma[SDV.IB]Life Sciences [q-bio]/BioengineeringSarcomaRadiodermatitisReoperationmedicine.medical_specialtyPrognostic-Factors[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineSpermatic cord03 medical and health sciencesTherapeutic approachHumansRadiology Nuclear Medicine and imagingIMRTAgedRetrospective StudiesRadiotherapybusiness.industryCancermedicine.diseaseRadiation-TherapySurgeryRadiation therapyRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessLigationOrchiectomyRare diseaseFollow-Up StudiesCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
researchProduct

Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer

2016

International audience; Background: To determine whether dose/volume specific endpoints (DVSE) or Area under the rectal DVH curve (rAUC) better predict acute gastrointestinal (GI) toxicity in prostate cancer patients treated with IMRT in the era of daily image guidance (IG-IMRT). Methods: A set of DVSE was recorded from V25 to V75 (increments of 5Gy) (both in % and in cc) for 180 men. The rAUC was calculated for doses ranging between 25Gy and 50Gy (rAUC(25-50)). Univariate and multivariate logistic regressions were performed to determine the relationship between DVSE or rAUC(25-50) and the appearance of any acute GI toxicity. Results: The rates of acute grade 1 (G1), G2 and G3 GI toxicities…

OncologyMale[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentGastroenterology030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineProstate cancer0302 clinical medicineProstateLarge intestineConformal Radiation-Therapy[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingAged 80 and overGastrointestinal tractProstate cancerRadiotherapy DosageMiddle Aged3. Good healthmedicine.anatomical_structureImpactOncologyRadiology Nuclear Medicine and imaging030220 oncology & carcinogenesisArea Under CurveToxicityImage Guidancemedicine.medical_specialtyRectum[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciencesInternal medicinemedicineBiochemical ControlHumansRadiology Nuclear Medicine and imagingRadiation InjuriesAgedRadiotherapybusiness.industryResearchRectumProstatic Neoplasmsmedicine.diseaseRadiation therapyAcute rectal toxicity predictive factorLogistic ModelsRadiotherapy Intensity-ModulatedbusinessAbsolute volumeRadiation Oncology (London, England)
researchProduct

Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index les…

2015

Abstract Purpose To determine whether post-implant MRI-based dosimetry of the Dominant Intra-prostatic Lesion (DIL) could best predict the occurrence of PSA bounce after prostate brachytherapy. Methods and materials We selected 66 patients with a low risk prostate cancer treated with 125 I prostate brachytherapy as monotherapy. Post-implant dosimetry based on day 30 CT-scan and multiparametric MRI co-registration was generated: planned D 90, D 95, V 100, V 150 values were calculated for each DIL. Bounce was defined as a PSA elevation ⩾0.2ng/mL from the previous baseline value followed by a decrease to or below the prior nadir with no additional treatment. Results After a median follow-up of…

Malemedicine.medical_treatmentBrachytherapyBrachytherapyIodine RadioisotopesProstate cancerProstatemedicineHumansDosimetryRadiology Nuclear Medicine and imagingRadiometryAgedRetrospective StudiesIndex Lesionmedicine.diagnostic_testbusiness.industryProstateProstatic NeoplasmsRadiotherapy DosageMagnetic resonance imagingHematologyMiddle AgedProstate-Specific Antigenmedicine.diseaseMagnetic Resonance ImagingProstate-specific antigenTreatment Outcomemedicine.anatomical_structureOncologyTomography X-Ray ComputedNuclear medicinebusinessProstate brachytherapyFollow-Up StudiesRadiotherapy and Oncology
researchProduct

Focal or whole-gland salvage prostate brachytherapy with iodine seeds with or without a rectal spacer for postradiotherapy local failure: How best to…

2016

International audience; PURPOSE: Salvage prostate permanent implant (sPPI) for postradiation local failure provides high rates of biochemical control. The cumulative dose delivered to the prostate and the rectum is still unknown. METHODS AND MATERIALS: We reviewed the postimplant CT-based dosimetry of 18 selected patients who underwent sPPI with I-125 seeds for isolated biopsy-proven local failure several years after external beam radiation therapy. Ten patients had whole-prostate sPPI, and 8 patients had multiparametric MRI-based focal sPPI. In 8 patients, hyaluronic acid (HA) gel was injected into the prostate rectum space. RESULTS: The median cumulative biological effective dose after EB…

MaleOrgans at Risk[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentBrachytherapySalvage therapyRecommendationsAlpha/Beta030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineIodine RadioisotopesBiologically effective doseProstate cancer0302 clinical medicineProstatePositron Emission Tomography Computed Tomography[ SDV.IB ] Life Sciences [q-bio]/BioengineeringHyaluronic Acid[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingProstate cancerCumulative doseCancer RecurrencesRadiotherapy DosageMenLow dose rateMiddle AgedImplantation3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesis[SDV.IB]Life Sciences [q-bio]/BioengineeringLocal failureProstate brachytherapymedicine.medical_specialtyBrachytherapyRectum[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineRadiation Dosage03 medical and health sciencesPermanent BrachytherapymedicineHumansProctitisRadiology Nuclear Medicine and imagingRadiation InjuriesProctitisAgedSalvage TherapySalvage brachytherapyRadiotherapybusiness.industryRadiotherapy Planning Computer-AssistedCarcinomaRectumProstatic Neoplasmsmedicine.diseaseRadiation-TherapySurgeryNeoplasm Recurrence LocalTomography X-Ray ComputedNuclear medicinebusinessGels
researchProduct

Radiothérapie guidée par l’image des cancers prostatiques : concepts et implications

2012

Resume La radiotherapie conformationnelle avec modulation d’intensite (RCMI) et la radiotherapie guidee par l’image sont deux evolutions technologiques qui, appliquees au modele des cancers prostatiques, ont permis de voir diminuer significativement la toxicite et les sequelles digestives et urinaires de la radiotherapie conformationnelle tridimensionnelle. Le benefice clinique majeur de ces techniques sur la diminution de la toxicite digestive et urinaire est indiscutable puisque les sequelles observees a dix ans sont devenues rares avec ces techniques (2 % de cas de toxicite digestive de grade 2 et 1 % de grade 3, 11 % de cas de toxicite urinaire de grade 2 et 5 % de grade 3). Si ces deux…

OncologyRadiology Nuclear Medicine and imagingCancer/Radiothérapie
researchProduct

Pattern of occult nodal relapse diagnosed with 18F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only rad…

2014

Abstract Introduction The purpose of this study was to describe the pattern of nodal relapse with 18 F-fluoro-choline (FCH) Positron Emission Tomography/Computerized Tomography (PET/CT) in prostate cancer patients after radiotherapy. Materials and methods Eighty-three patients had a FCH PET/CT at time of biochemical failure. Of 65 patients with positive findings, 33 had positive nodes. This analysis included 31 patients who had undergone prior prostate-only radiotherapy with or without a prior radical prostatectomy. Each FCH positive node was assigned to a lymph node station with respect to the CTV defined by the RTOG guidelines (CTV RTOG ). 3D mapping was performed after each node was manu…

MaleFluorine Radioisotopesmedicine.medical_treatment[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineMultimodal Imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineCholineProstate cancerProstatemedicineHumansRadiology Nuclear Medicine and imagingLymph nodeComputingMilieux_MISCELLANEOUSSalvage TherapyPET-CTmedicine.diagnostic_testProstatectomybusiness.industryProstatic NeoplasmsHematologyProstate-Specific Antigenmedicine.diseaseOccult3. Good healthRadiation therapymedicine.anatomical_structureOncologyPositron emission tomographyLymphatic MetastasisPositron-Emission TomographyKallikreinsLymph NodesNeoplasm Recurrence LocalRadiopharmaceuticalsNuclear medicinebusinessTomography X-Ray Computed
researchProduct

Multiparametric MRI-based Dosimetric Parameters Best Predict Short-term Time Course of PSA After Iodine 125 Permanent Prostate Implantation for Local…

2012

International audience; D90% and V150% of the entire prostate are recognized as the best dosimetric predictors of outcome after 125 I permanent prostate implantation (PPI). The purpose of this study was 2-fold: 1) to determine the relationship between dose-volume parameters of the Dominant Intraprostatic Lesion (DIL) when compared to the prostate and early biochemical outcome after PPI; 2) to define if dose-volume parameters of the central gland (CG), the peripheral zone (PZ) and the DIL could best predict PSA bounce occurrence. The time course of PSA and mechanisms of bounces still remain unclear after PPI. Patients who had a higher dose in the DIL had a worse PSA level at 1 year which is …

Entire prostateCancer Researchmedicine.medical_specialtyProstate implantationUrology[INFO.INFO-IM] Computer Science [cs]/Medical Imaging030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineProstatemedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingRadiology Nuclear Medicine and imagingRadiation[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingbusiness.industryMultiparametric MRIPSA bouncemedicine.diseasePeripheral zonemedicine.anatomical_structureOncology030220 oncology & carcinogenesisTime coursebusiness
researchProduct

Impact of rectal distension on prostate CBCT-based positioning assessed with 6 degrees-of-freedom couch

2018

International audience; Introduction: Prostate requires a daily correction of its 3-dimensional position in relation with rectal distension. In this study, we sought to determine whether rectal distension with respect to the rectal behavior might have an impact on prostate translations and/or rotations during prostate image guided radiation therapy using a 6 degrees-of-freedom (DOF) couch.Methods and materials: We reviewed the data from 39 patients with localized prostate cancer treated with protracted external radiation therapy using a 6 DOF couch. Before each fraction, a kilovoltage cone beam computed tomography (kV-CBCT) scan was performed. The automatic fusion algorithm was set to fuse …

MaleKilovoltage Cone Beam Computed Tomography[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatment78 GyFailureRectum[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineIncreased RiskStandard deviationPatient PositioningTrial030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineProstatemedicineHumansRadiology Nuclear Medicine and imagingConformal Radiation-TherapyImage-guided radiation therapyCancerContouringbusiness.industryImage-GuidanceRadiotherapy Planning Computer-AssistedAcute ToxicityProstateRectumProstatic NeoplasmsRadiotherapy DosageExternal-Beam RadiotherapyCone-Beam Computed Tomographymedicine.diseaseRadiation therapymedicine.anatomical_structureOncology030220 oncology & carcinogenesisFeasibility StudiesRadiotherapy Intensity-ModulatedStrategiesbusinessNuclear medicineTomography X-Ray ComputedRadiotherapy Image-Guided
researchProduct

Inferring postimplant dose distribution of salvage permanent prostate implant (PPI) after primary PPI on CT images

2018

International audience; PURPOSE:To evaluate the dose distribution of additional radioactive seeds implanted during salvage permanent prostate implant (sPPI) after a primary permanent prostate implant (pPPI).METHODS AND MATERIALS:Patients with localized prostate cancer were primarily implanted with iodine-125 seeds and had a dosimetric assessment based on day 30 postimplant CT (CT1). After an average of 6 years, these patients underwent sPPI followed by the same CT-based evaluation of dosimetry (CT2). Radioactive seeds on each CT were detected. The detected primary seeds on CT1 and CT2 were registered and then removed from CT2 referred as a modified CT2 (mCT2). Dosimetry evaluations (D90 and…

MaleBrachytherapy[SDV.CAN]Life Sciences [q-bio]/CancerDose distribution[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology030218 nuclear medicine & medical imagingIodine Radioisotopes03 medical and health sciencesProstate cancer0302 clinical medicineProstateDosimetryIodine seedsmedicineHumansDosimetryRadiology Nuclear Medicine and imagingRadiometrySalvage TherapyPrimary permanentSalvage brachytherapyProstate cancerbusiness.industryProstateProstatic NeoplasmsProstate implantRadiotherapy Dosagemedicine.disease3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisTomography X-Ray ComputedbusinessNuclear medicineSalvage brachytherapy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxe…

2010

There is currently no standard of treatment for patients with hormone refractory prostate cancer (HRPC) after failure of docetaxel-based chemotherapy. The purpose of this study was to assess the anticancer activity and tolerance of metronomic cyclophosphamide prednisolone combination in this setting.From 2005 to 2010, patients with HRPC who failed at least docetaxel-based chemotherapy were proposed metronomic cyclophosphamide-prednisolone regimen, and were prospectively registered. Twenty-three patients received 50 mg cyclophosphamide and 10 mg prednisolone per os daily until disease progression. Treatment tolerance and efficacy on PSA decrease and pain were studied.Metronomic cyclophospham…

Male[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Antineoplastic Combined Chemotherapy ProtocolsMESH: Treatment FailurePrednisoloneMESH : MaleMESH : PrednisoloneMESH: TaxoidsMESH : AgedMESH : Prospective StudiesDocetaxelMESH : Treatment OutcomeMESH : Treatment FailureMESH: Aged 80 and overAntineoplastic Combined Chemotherapy ProtocolsHumans[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : Middle AgedProspective StudiesTreatment FailureMESH : Prostate-Specific AntigenMESH : Aged 80 and overMESH : TaxoidsCyclophosphamideMESH : Cyclophosphamidehealth care economics and organizationsAgedMESH: Treatment OutcomeAged 80 and overMESH: AgedMESH: HumansMESH: Middle AgedMESH : HumansProstatic NeoplasmsMESH: CyclophosphamideMiddle AgedProstate-Specific AntigenMESH: MaleMESH: Prospective StudiesMESH: Prostate-Specific AntigenMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeMESH: Prostatic Neoplasms[SDV.IMM]Life Sciences [q-bio]/ImmunologyTaxoidsMESH: PrednisoloneMESH : Prostatic Neoplasms
researchProduct